We are analyzing https://link.springer.com/article/10.1007/s11864-017-0443-7.

Title:
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer | Current Treatment Options in Oncology
Description:
Single-agent endocrine therapy has been the standard therapeutic choice for the management of hormone receptor (HR)-positive, Her2-negative advanced breast cancer (ABC) for decades. However, the rapidly accumulating data regarding the biological role and safety of CDK4/6 inhibitors and the first-in-class approval of palbociclib have made these novel agents an essential component of treatment for HR-positive ABC. In the frontline setting, palbociclib in combination with endocrine therapy showed an improvement in progression-free survival (PFS) by 10 months to nearly 25 months when compared with endocrine therapy alone and a clinical benefit rate (CBR = stable disease >24 weeks + partial response + complete response) of 85%. Furthermore, clinically meaningful improvements in PFS were seen in combination with fulvestrant for patients with prior endocrine therapy, including premenopausal women. While neutropenia is experienced by most patients, it is typically uncomplicated and palbociclib is otherwise well tolerated. Recent analysis also demonstrated improved quality of life and reassuring evidence of no compromise in benefit from subsequent therapies after progression on palbociclib. Along with palbociclib, the CDK4/6 inhibitors ribociclib and abemaciclib are being evaluated in a variety of settings (metastatic, neoadjuvant, and adjuvant), alone and in combination with endocrine therapy, chemotherapy, and targeted therapies. Future research is needed to address challenges regarding the potential competition of these agents as the preferred partner in endocrine-sensitive disease, their use as single agents or in combination in the endocrine-refractory setting, and the clinical and molecular criteria for use as an alternative to chemotherapy. Unfortunately, despite efforts to determine predictive biomarkers for response, RB1 expression and HR-positive disease have been the only clear predictors of therapeutic benefit. Once more mature data become available, we hope to confirm a significant impact on long-term survival. Meanwhile, given the multiple therapies patients with ABC will receive, prolonged PFS with a well-tolerated oral regimen is a clinically meaningful endpoint. Palbociclib’s impact on PFS, high CBR, and tolerability have made its use a preferred option for treating many HR-positive, Her2-negative ABC patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,643,078 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cancer, article, breast, google, scholar, pubmed, cas, cdk, palbociclib, phase, advanced, inhibitor, patients, endocrine, therapy, kinase, cell, combination, clinical, oncology, cyclindependent, journal, metastatic, treatment, hernegative, trial, central, study, data, ribociclib, hormone, receptorpositive, cristofanilli, abemaciclib, oncol, human, res, inhibitors, hrpositive, rev, activity, efficacy, suppl, content, shah, therapeutic, abc, safety, fulvestrant, therapies,

Topics {✒️}

semi-mechanistic pharmacokinetic/pharmacodynamic modeling month download article/chapter targeted therapy + endocrine therapy her2-targeted therapies cyclin-dependent kinase pathways eralpha-dependent e2f transcription hr+/her2- breast cancer cyclin-dependent kinase inhibitor hormone receptor positive hormone-receptor–positive hormone-receptor-positive included pre-menopausal women estrogen receptor-positive joint hormone receptor org/professionals/physician_gls/f_guidelines massimo cristofanilli md breast cancer access her2-negative abc patients cyclin-dependent kinases 4 advanced breast cancer oestrogen receptor-positive hr-positive disease subsequent therapies targeted therapies full article pdf metastatic breast cancer � finn rs cyclin-dependent kinase 4/6 her2- breast cancer human tumor xenografts human breast cancer kinase-independent function cdk4/6 inhibitors ribociclib endocrine-sensitive disease her2-negative abc human breast tumours multiple therapies patients acquired endocrine resistance privacy choices/manage cookies hormone receptor breast cancer pathogenesis cell cycle transcription breast cancer res community oncology network clinical cancer research endocrine therapy showed prior endocrine therapy versus endocrine therapy previous endocrine therapy nat rev cancer

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
         description:Single-agent endocrine therapy has been the standard therapeutic choice for the management of hormone receptor (HR)-positive, Her2-negative advanced breast cancer (ABC) for decades. However, the rapidly accumulating data regarding the biological role and safety of CDK4/6 inhibitors and the first-in-class approval of palbociclib have made these novel agents an essential component of treatment for HR-positive ABC. In the frontline setting, palbociclib in combination with endocrine therapy showed an improvement in progression-free survival (PFS) by 10 months to nearly 25 months when compared with endocrine therapy alone and a clinical benefit rate (CBR = stable disease >24 weeks + partial response + complete response) of 85%. Furthermore, clinically meaningful improvements in PFS were seen in combination with fulvestrant for patients with prior endocrine therapy, including premenopausal women. While neutropenia is experienced by most patients, it is typically uncomplicated and palbociclib is otherwise well tolerated. Recent analysis also demonstrated improved quality of life and reassuring evidence of no compromise in benefit from subsequent therapies after progression on palbociclib. Along with palbociclib, the CDK4/6 inhibitors ribociclib and abemaciclib are being evaluated in a variety of settings (metastatic, neoadjuvant, and adjuvant), alone and in combination with endocrine therapy, chemotherapy, and targeted therapies. Future research is needed to address challenges regarding the potential competition of these agents as the preferred partner in endocrine-sensitive disease, their use as single agents or in combination in the endocrine-refractory setting, and the clinical and molecular criteria for use as an alternative to chemotherapy. Unfortunately, despite efforts to determine predictive biomarkers for response, RB1 expression and HR-positive disease have been the only clear predictors of therapeutic benefit. Once more mature data become available, we hope to confirm a significant impact on long-term survival. Meanwhile, given the multiple therapies patients with ABC will receive, prolonged PFS with a well-tolerated oral regimen is a clinically meaningful endpoint. Palbociclib’s impact on PFS, high CBR, and tolerability have made its use a preferred option for treating many HR-positive, Her2-negative ABC patients.
         datePublished:2017-02-14T00:00:00Z
         dateModified:2017-02-14T00:00:00Z
         pageStart:1
         pageEnd:16
         sameAs:https://doi.org/10.1007/s11864-017-0443-7
         keywords:
            CDK4/6 inhibitors
            Palbociclib
            Ribociclib
            Abemaciclib
            Hormone receptor-positive advanced breast cancer
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11864-017-0443-7/MediaObjects/11864_2017_443_Fig1_HTML.gif
         isPartOf:
            name:Current Treatment Options in Oncology
            issn:
               1534-6277
               1527-2729
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Ami N. Shah
               affiliation:
                     name:Feinberg School of Medicine
                     address:
                        name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Massimo Cristofanilli
               affiliation:
                     name:Feinberg School of Medicine
                     address:
                        name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
      description:Single-agent endocrine therapy has been the standard therapeutic choice for the management of hormone receptor (HR)-positive, Her2-negative advanced breast cancer (ABC) for decades. However, the rapidly accumulating data regarding the biological role and safety of CDK4/6 inhibitors and the first-in-class approval of palbociclib have made these novel agents an essential component of treatment for HR-positive ABC. In the frontline setting, palbociclib in combination with endocrine therapy showed an improvement in progression-free survival (PFS) by 10 months to nearly 25 months when compared with endocrine therapy alone and a clinical benefit rate (CBR = stable disease >24 weeks + partial response + complete response) of 85%. Furthermore, clinically meaningful improvements in PFS were seen in combination with fulvestrant for patients with prior endocrine therapy, including premenopausal women. While neutropenia is experienced by most patients, it is typically uncomplicated and palbociclib is otherwise well tolerated. Recent analysis also demonstrated improved quality of life and reassuring evidence of no compromise in benefit from subsequent therapies after progression on palbociclib. Along with palbociclib, the CDK4/6 inhibitors ribociclib and abemaciclib are being evaluated in a variety of settings (metastatic, neoadjuvant, and adjuvant), alone and in combination with endocrine therapy, chemotherapy, and targeted therapies. Future research is needed to address challenges regarding the potential competition of these agents as the preferred partner in endocrine-sensitive disease, their use as single agents or in combination in the endocrine-refractory setting, and the clinical and molecular criteria for use as an alternative to chemotherapy. Unfortunately, despite efforts to determine predictive biomarkers for response, RB1 expression and HR-positive disease have been the only clear predictors of therapeutic benefit. Once more mature data become available, we hope to confirm a significant impact on long-term survival. Meanwhile, given the multiple therapies patients with ABC will receive, prolonged PFS with a well-tolerated oral regimen is a clinically meaningful endpoint. Palbociclib’s impact on PFS, high CBR, and tolerability have made its use a preferred option for treating many HR-positive, Her2-negative ABC patients.
      datePublished:2017-02-14T00:00:00Z
      dateModified:2017-02-14T00:00:00Z
      pageStart:1
      pageEnd:16
      sameAs:https://doi.org/10.1007/s11864-017-0443-7
      keywords:
         CDK4/6 inhibitors
         Palbociclib
         Ribociclib
         Abemaciclib
         Hormone receptor-positive advanced breast cancer
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11864-017-0443-7/MediaObjects/11864_2017_443_Fig1_HTML.gif
      isPartOf:
         name:Current Treatment Options in Oncology
         issn:
            1534-6277
            1527-2729
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Ami N. Shah
            affiliation:
                  name:Feinberg School of Medicine
                  address:
                     name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Massimo Cristofanilli
            affiliation:
                  name:Feinberg School of Medicine
                  address:
                     name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Current Treatment Options in Oncology
      issn:
         1534-6277
         1527-2729
      volumeNumber:18
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Feinberg School of Medicine
      address:
         name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Feinberg School of Medicine
      address:
         name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Ami N. Shah
      affiliation:
            name:Feinberg School of Medicine
            address:
               name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Massimo Cristofanilli
      affiliation:
            name:Feinberg School of Medicine
            address:
               name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
      name:Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(150)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.37s.

LINK . SPRINGER . COM {}